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Abstract 
The complexity of heparin and heparan sulfate saccharides makes their purification, including 
many isomeric structures, very challenging and is a bottleneck for structure-activity studies. High 
resolution separations have been achieved by strong anion exchange (SAX) chromatography on 
Propac PA1 and cetyltrimethylammonium (CTA)-C18 silica columns but these entail subsequent 
desalting methodologies, consequent sample losses and are incompatible with orthogonal 
chromatography methodologies and in particular mass spectrometry. Here we present the CTA-
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SAX purification of heparin oligosaccharides using volatile salt (VS) buffer. In VSCTA-SAX 
the use of ammonium bicarbonate buffer for elution improves resolution through both weaker 
dissociation and conformational co-ordination of the ammonium across the sulfate groups. Using 
ion-mobility mass spectrometry (IMMS) we demonstrate that isomeric structures have different 
structural conformations, which makes chromatographic separation achievable. Resolution of 
such structures is improved compared to standard SAX methods, and in addition VSCTA-SAX 
provides an orthogonal method to isolate saccharides with higher purity. Since ammonium 
bicarbonate is used, the samples can be evaporated rather than desalted, preventing substantial 
sample loss and allowing more effective subsequent analysis by electrospray-mass spectrometry 
(ESI-MS). We conclude that VSCTA-SAX is a powerful new tool which helps address the 
difficult challenge of heparin/HS saccharide separation, and will enhance structure-activity 
studies.  
 
Introduction 
Heparin and HS are part of the glycosaminoglycan (GAG) family of sugars. Heparin was 
first discovered in 1916 and then later developed into an anticoagulant based drug which was 
first used in 1935. Heparin and HS play an important role in the regulation of biological systems, 
with chemical synthesis, enzymatic synthesis and oligosaccharide purification are being used to 
obtain pure structures to understand structure-function relationships1-5. Heparin and HS are 
highly anionic structures, with their synthesis being non-template driven with enzymatic 
specificity creating variable sulfated regions and acetylated regions identified in HS. Sulfate 
groups can reside on the 2-O position of the uronic acid group, and the 6-O, 3-O and N-position 
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of the glucosamine, with the N-positions also able to adopt an acetate group and occasionally an 
amine. It is this micro-heterogeneity in sulfation that changes between organs6, stage of 
development7-8, communication and environment9, providing heparin and HS with a dynamic 
conformational versatility and thus a vast range of biological functions10.  
Size exclusion chromatography (SEC) is often the first method used in heparin / HS 
oligosaccharide purification11. SEC separation depends not just on the number of saccharide 
units, but also on the number of sulfate groups, thus increasing the likelihood of oligosaccharides 
with different sequences and structures having equivalent hydrodynamic radii12. Nevertheless, in 
isolation of structures ranging from dp4 to dp12, SEC will separate roughly in dp2 increments, 
due to the disaccharide cleavage specificity of various depolymerisation methods13. Further 
purification of structures isolated by SEC is most commonly achieved using strong anion 
exchange (SAX).  
SAX is a powerful heparin/HS separation method, as it offers higher oligosaccharide 
resolution over other methods currently available, including hydrophilic interaction 
chromatography (HILIC)14, reverse phase ion pairing  (RP-IP)15-16, and capillary electrophoresis 
(CE)17-18. With small saccharides (for example disaccharides), there is a significant degree of 
separation dependant on the presence of 2OS, 6OS and NS groups, but as the oligosaccharide 
becomes longer this resolution decreases19, necessitating the use of additional SAX or orthogonal 
chromatography methods. 
Cetyltrimethylammonium SAX (CTA-SAX) is an alternative SAX method which uses a 
C8 or C18 column matrix derivatised with CTA20-21. The coating of CTA is dynamic and fine 
tuning of this coat results in the resolution of oligosaccharides containing up to 20 sulfate groups. 
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The extent of CTA derivatisation is determined by the water-methanol (v/v) concentration that 
the column is derivatised in. However, a drawback of this method arises from the use of the 
ammonium methane sulphonic acid mobile phase at pH 2.5 to create the eluting gradient. This 
method has not been widely used due to the difficulty in producing the derivatised column, 
weaker functional end groups and acidic elution. 
RP-IP chromatography is also used to separate oligosaccharides, using di-, tri-, butyl- 
amines22. All eight disaccharides can be separated using a tri-butyl quaternary amine23 and for 
larger oligosaccharides a tri-ethyl amine is generally used as the ion pairing agent24. This method 
has been employed in the analysis of sugars from model organisms, such as Caenorhabditis 
elegans and Drosophila25. It has also been used in the compositional analysis of HS from human 
tissues, such as liver26 and in pharmacokinetics in the analysis of contaminated oral heparin27. 
RP-IP has high resolving capabilities, but removal of the ion pairing reagent is problematic,  
resulting in oligosaccharide losses through desalting and causing in-source contamination when 
coupled with a mass spectrometer.   
Heparin and HS have polar carboxylates, sulfates and hydroxyl groups and are good 
candidates for the HILIC technique28, where HILIC has been used to separate a wide range of 
GAG saccharides, as well as O-glycans and N-glycans29-31. Recently HILIC LC-MS has been 
used in the analysis of GAGs from tissues, with studies focusing on CS (chondroitin sulfate) / 
DS (dermatan sulfate) in connective joint tissues14, 32 and profiling heparin and HS33-37, using the 
parent ion and collision induced dissociation (CID) differences. HILIC uses volatile buffers and 
is compatible with mass spectrometry, but has low oligosaccharide resolution.  
In this paper, we describe an ammonium based (volatile salt) CTA-SAX method in 
conjunction with SEC and conventional SAX that provides improved separation of isomeric 
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heparin oligosaccharides. The purification of heparin oligosaccharides using the VSCTA-SAX 
method avoids the need for desalting, improves column resolution, and the products are directly 
compatible with mass spectrometry analysis.  
Methods 
Materials and Reagents. All chemicals of analytical or HPLC grade purity were 
purchased from Sigma (Gillingham, UK) and VWR (Lutterworth, UK) unless otherwise stated. 
Disaccharides standards 1-8 were purchased from Iduron (Manchester, UK). Heparin was 
purchased from Alfa Asear (Massachusetts, USA). Heparinase I, II, and III enzymes were 
purchased from IBEX (Canada).  
Disaccharide CTA-SAX chromatography. CTA-SAX was performed based on the 
method of Mourier & Viskov (2004) utilising a Discovery C18 silica column (250 x 4.6 mm, 5 
µm, Supelco) which was derivatised with 1 mM cetyltrimethylammonium in a water:methanol 
ratio of 50:50 v/v. Separations were performed using the Shimadzu SPD 10A instrument using a 
UV-visible spectrophotometric detector. Eluent A was HPLC grade water, pH 3, using methane 
sulphonic acid and eluent B was ammonium methane sulphonic acid (2 M), pH 2.5. The elution 
profiles were monitored by absorbance at 232 nm. Eight commonly occurring authentic HS 
disaccharides (Dextra Labs) were injected and eluted with a 0-50 % linear gradient of eluent B at 
a flow rate of 1 mL/min over 60 minutes. The disaccharide separation was repeated using HPLC 
grade water as eluent A and 2 M ammonium bicarbonate as eluent B. 
Digestion of heparin. Heparin (1 g) was dissolved in 500 µL of lyase buffer (100 mM 
sodium acetate, 10 mM calcium acetate) and digested into oligosaccharide products using 1 mU 
of heparinase I (1 mU per 1µL) to 10 mg of heparin at 37 oC. At 2, 3, 4, 6 and 8 hours, a 120 µL 
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aliquot was taken from the reaction and quenched by denaturing the heparinase enzyme at 98 oC 
for 3 minutes. The resulting products were pooled and further separated as described below.  
Size exclusion chromatography (SEC). Heparin was separated using a Biorad Econo 
column packed in-house with prep grade Sephadex 30 beads (15 mm x 170 cm, bead size 34 µm 
- GE Healthcare) on a Delta 600 HPLC system (Waters). A 500 mg sample of the pooled 
digested heparin, was made up to 1 mL with 0.5 M ammonium bicarbonate and injected into the 
system. The digested heparin sample was eluted using 0.5 M ammonium bicarbonate with a flow 
rate of 0.1 mL/min. The elution profile was monitored with absorbance at 232 nm. Fractions 
were pooled and repeatedly freeze-dried using water until all the ammonium bicarbonate was 
removed.  
Strong Anion-Exchange Chromatography (SAX). SEC fractions were separated using 
a Propac PA1 column (4.6 mm x 250 mm, 5 µm bead size; Thermo Scientific) on a Delta 600 
HPLC system (Waters). Eluent A was HPLC grade water and eluent B was 2 M NaCl. The 
concentration of each oligosaccharide fraction loaded was dependent on its previous purification 
method, as stated in the text. The initial hexa-saccharide separation was performed on a 0-1.4 M 
NaCl gradient over 90 minutes using the Propac PA1 column. Subsequent bespoke elution 
gradients for each oligosaccharide were calculated based on the first round of SAX separation. 
Isolated peaks were collected and subjected to further orthogonal techniques. 
Oligosaccharide VSCTA-SAX chromatography. The C18 column (4.6 mm x 250 mm, 
5 µm bead size - Sigma) was derivatised with 1 mM cetyltrimethylammonium in a water: 
methanol ratio of 40: 60 (v/v). Oligosaccharides collected from the Propac PA1 SAX column 
separation were diluted 1 in 10 and multiple injections were performed to load the entire sample 
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onto the VSCTA-SAX column. VSCTA-SAX separations were performed using a Waters Delta 
600 HPLC with a UV-visible spectrophotometric detector. Eluent A was HPLC grade water and 
eluent B was 2 M ammonium bicarbonate using a flow rate of 1 mL/min, at a temperature of 40 
oC. The elution profiles were monitored with an absorbance at 232 nm. Gradient details for each 
sample are in the text and figure legends. Each fraction was dried on a SPD121B speed vac 
(Thermo Scientific) prior to mass spectrometry and compositional analysis. 
Disaccharide compositional analysis. Purified oligosaccharide structures were digested 
using 10 µL of 1 mU / 1µL, heparinase I, heparinase II and heparinase III. Each reaction was 
incubated at 30 oC for 24 hours to achieve complete digestion. The resulting disaccharide 
products were then separated on a SAX Propac PA1 (4.6 mm x 250 mm, 5µm bead (Dionex)) 
column using a Waters Delta 600 HPLC with a UV-visible spectrophotometric detector. Each 
sample was separated on a 0-1 M NaCl gradient over 60 minutes. Elution profiles were 
monitored with an absorbance of 232 nm. Disaccharide standards (1 µg of each standard) were 
loaded on to the same SAX Propac PA1 column and separated using the same gradient, so that 
the samples could be compared. 
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IMMS of isomeric hexasaccharides. IMMS was performed on a Synapt G1 mass 
spectrometer equipped with a T-wave mobility cell (Waters Corp., Milford, MA). Sample 
concentration was calculated based on its 232 nm absorbance and then adjusted to a 
concentration of 0.5 µM in water/acetonitrile (50/50 v/v) with 500 mM ammonium hydroxide. 
The borosilicate tips were made in house as stated in previous publications38-39. Oligosaccharides 
were sprayed in a borosilicate gold coated tip and mass spectra were acquired in negative ion 
mode with a capillary voltage at 0.55 kV, a sample cone voltage at 7 V, and an extraction cone 
voltage at 0.6 V. The ion mobility parameters for each tetra or hexasaccharide can be found in 
supplementary materials. MS/MS was performed on selected ions and collisionally activated at 
15 V and 20 V in the transfer cell with the mobility cell turned off in order to produce 
comparable CID data for each isomer.  
	  
Results and discussion 
Disaccharide analysis by CTA-SAX employing volatile buffers 
The natural diversity of heparin and HS provides a rich source for structure-function 
studies, but many oligosaccharides are isomeric structures, making purification difficult. This 
arises from the structures having identical  negative charge, and is compounded as the chain 
length increases12, 40. The separation problems deepen due to the molecule being linear, and the 
distance between the groups being close41-42. As the number of adjacent negative charges 
increase, the charge-charge repulsion makes this task even more difficult. Low pH buffers (eg. 
pH 1) result in protonation of 50 % of the sulfate groups and 99 % of the carboxylic acid groups, 
potentially altering conformation and interaction with columns. At neutral pH, most sulfate 
groups will be negatively charged causing charge-charge repulsion, as well as adduct retention. It 
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is known that co-ordination of salts causes different structural conformations43, so here we used 
ammonia-based salts to enhance the level of diversity for isomeric separation. The other major 
obstacle for purification is the use of non-volatile salt buffers, which necessitates subsequent 
desalting  methods which for hydrophilic  HS oligosaccharides result in interactions and material 
loss (with desalting columns recoveries of only 60-70% were observed compared to > 90% 
recovery with the VSCTA SAX; data not shown). Non-volatile salts also affect mass 
spectrometry analysis, by increasing the number of adducts attached to the sulfate groups , and 
via signal suppression. We reasoned that the use of a volatile salt SAX method would overcome 
these problems. A conventional SAX method using Propac PA1 column was tested with volatile 
ammonium bicarbonate salts; however, neither disaccharides nor oligosaccharides eluted from 
the column, indicating the interaction was too strong for ammonium bicarbonate to achieve 
effective dissociation (data not shown). To overcome this, we investigated CTA-SAX19, in which 
a C-18 reverse phase column is first derivatised using CTA, imparting a positive charge on the 
matrix and allowing the column to be used for SAX. Firstly, eight commonly occurring HS 
disaccharide standards were separated on CTA-SAX using a 0-1 M ammonium methane sulfonic 
acid gradient over 60 minutes (Figure 1a). All disaccharides eluted with baseline resolution; 
furthermore, the column separated α and β anomers for the disaccharides, resulting in double 
peaks for many of the standards. The standards were then separated on the CTA-SAX column 
using the volatile ammonium bicarbonate salt (Figure 1b). As with the ammonium methane 
sulfonic acid, all 8 disaccharides were separated, but without separation of the anomeric 
structures with the minor drawback of increased baseline absorbance. The ability of the 
ammonium bicarbonate to dissociate disaccharides from the CTA-SAX column but not the 
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Propac PA-1 column suggested that the VSCTA-SAX system might be ideal as an additional 
purification step for oligosaccharides.  
Major and minor oligosaccharide peak separation 
To prove the effectiveness of VSCTA-SAX to prevent losses, improve separation, and 
increase compatibility with other techniques such as mass spectrometry, we isolated a heparin 
hexasaccharide using traditional SEC and SAX followed by VSCTA-SAX, and determined its 
sequence using mass spectrometry. Full length heparin was digested with heparinase I and the 
oligosaccharide mixture (ranging from dp2 – dp30) was  separated using SEC (data not shown). 
The dp6 oligosaccharide fraction isolated from SEC separation was subjected to further 
chromatographic separation using Propac PA1 SAX (Figure 2). Separation of the dp6 SEC 
fraction is shown in Figure 2; peaks A, B and C were selected for further purification. Previous 
work has focused on using such partially resolved SAX fractions 44.  
Peak A was separated further using a Propac PA1 column employing a shallower salt 
elution gradient to improve oligosaccharide resolution (Figure 3a). However, using this gradient 
full oligosaccharide separation could not be obtained. Peak D from this run was then further 
separated by VSCTA-SAX chromatography using ammonium bicarbonate as the elution buffer, 
demonstrating resolution of two separate oligosaccharide structures (Figure 3b). The reasons for 
these two peaks being separated could be related to the spacing of the CTA linker on the column, 
or because an ammonium salt is weaker in its displacement than a sodium salt. It could also be 
because ammonium ions are known to co-ordinate and separate oligosaccharides differently to 
sodium adducts as shown through graphite LC-MS (Miller, Karlsson & Turnbull, unpublished 
data). The larger peak, peak E (Figure 3b), was selected for mass spectrometry analysis and 
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compositional analysis to determine whether the structure was pure and establish whether it 
could be sequenced (Figures 3c to 3e). MS showed that this peak was pure, with a m/z 509.9 [M-
3H]3-, which corresponds to a hexasaccharide with 6 sulfates and 1 acetyl group (dp6 + 6SO3 + 
1Ac; Figure 3c). Data from tandem mass spectrometry and compositional analysis were both 
used to inform sequencing (Figure 3d and 3e)45-48. Compositional analysis of peak E (Figure 3e), 
showed that this structure contains three different disaccharides: a ∆UA - GlcNAc6S, a ∆UA2S - 
GlcNS, and a ∆UA2S - GlcNS6S. The order of the disaccharides can be determined based on the 
acetate group, as this does not dissociate in the mass spectrometer and displays a distinct mass 
signature compared to sulfate groups. The ions m/z 486 (Y3, UA - GlcNAc6S - UA2S - GlcNS), 
429.7 (C5, ∆UA2S - GlcNS6S - UA - GlcNAc6S - UA2S), and 636 (B5, ∆UA2S - GlcNS6S - 
UA - GlcNAc6S - UA2S), show that the GlcNAc is positioned in the middle of the structure and 
that the GlcNS is at the reducing terminal. If the GlcNAc residue was the reducing terminal 
disaccharide, it would be expected that ions corresponding to m/z 536 (C4), 615 (B5), and 624 
(C5), would be observed; none of these ions were observed in the product ion spectra. Therefore, 
the sequence can be defined as ∆UA2S - GlcNS6S - UA - GlcNAc6S - UA2S - GlcNS (Figure S-
1). 
Separation of isomeric structures  
The majority of structures within heparin and HS have multiple isomers, due to variation 
in positioning of sulfate and acetate groups in different saccharides of the same mass, making 
isolation of single structures challenging. For example peak B (Figure 2), clearly contains 
multiple species and has peak shoulders, and therefore likely represents multiple oligosaccharide 
structures. To tackle this problem, the middle peak was collected with the aim of isolating the 
major product with only minor overlapping products. Peak B (Figure 2) was separated a second 
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time using the SAX column with a shallower gradient (0.6 – 1.1 M NaCl over 60 minutes) in an 
effort to improve its separation (Figure 4a). In this case a greater level of separation was 
observed. It is likely that the resolving power of these peaks could be further enhanced by using 
a shallower salt gradient and reduced sample loading. Since the resulting major peak (peak F) 
was not baseline resolved, as commonly observed for heparin/HS oligosaccharides11, there is a 
need  to have additional orthogonal separation methodologies. To avoid desalting and 
consequent losses, peak F (containing a high concentration of NaCl) was loaded onto the 
VSCTA-SAX column through dilution and multiple injections. Peak F oligosaccharide structures 
were then eluted from the VSCTA-SAX column with a 0.7 – 1.4 M ammonium bicarbonate 
gradient (Figure 4b). This method of separation resulted in close to base line resolution of four 
apparent oligosaccharide compounds, demonstrating the enhanced resolution of VSCTA-SAX 
chromatography. The ammonium bicarbonate salt was removed readily via centrifugal 
evaporation (data not shown). Peak G and peak H were analysed by offline ESI-MS. They both 
displayed a m/z of 549.3, confirming that they were mass isomers as anticipated, and 
corresponding to a dp6 with 8SO3 (Figure 4c). Furthermore, IM-MS of peak G and peak H 
revealed that they displayed different arrival time distributions (ATDs) of 3.39 ms and 3.67 ms 
respectively (Figure 4d). This suggests different structural conformations, with peaks G and H 
displaying more compact and extended conformations respectively. Since both compounds could 
be separated though a charge dependent interaction method, this result indicates that this 
separation is at least partly dependent on their different conformational properties.  
To further determine the structure of the isolated peaks, tandem mass spectrometry and 
compositional analysis were performed on both peak G and peak H. MS revealed very different 
product ion spectra (Figure 4e). Compositional analysis showed that peak G contained a single 
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∆UA - GlcNS6S and two ∆UA2S - GlcNS6S disaccharides, whereas peak H contained one 
∆UA2S - GlcNS and two ∆UA2S - GlcNS6S (Figure 4f). Since there are two ∆UA2S -GlcNS6S, 
the first piece of information to identify in the product ion spectra is whether these disaccharides 
are adjacent. In peak G no doubly charged 576 product ion was observed (Figure 4e), whereas in 
peak H a doubly charged 576 product ion was observed, indicating that the two tri-sulfated 
disaccharides must be adjacent. Therefore, the sequence of peak H is ∆UA2S - GlcNS - UA2S - 
GlcNS6S - UA2S - GlcNS6S or ∆UA2S – GlcNS6S - UA2S - GlcNS6S - UA2S - GlcNS (Figure 
S-1 and S-2). In contrast, Peak G has a major triply charged product ion of 464 corresponding to 
Z4 (GlcNS6S - UA - GlcNS6S - UA2S - GlcNS6S). The Y3 ion (UA - GlcNS6S - UA2S - 
GlcNS6S) and Y2 ion (GlcNS6S - UA2S - GlcNS6S) confirmed that the UA – GlcNS6S is in the 
middle of the oligosaccharide structure (Figure 4e). Therefore, the sequence of the 
oligosaccharide isolated from peak G is ∆UA2S - GlcNS6S - UA - GlcNS6S - UA2S - GlcNS6S 
(Figures S-1 and S-2).  
In a further demonstration of the utility of VSCTA-SAX chromatography, we were also able to 
separate another three hexasaccharides (dp6 + 8SO3) from the same dp6 SEC fraction (peak C; 
Figure 2). This peak was further separated on a shallow gradient (0.84 – 1.2 M NaCl over 60 
minutes) on a SAX Propac PA1 column (Figure 5a). The structures were separated into two 
peaks, I and J (although not to baseline resolution) and were collected separately. It should be 
noted that collecting partial peaks and re-separating on a shallower gradient can also lead to 
improved resolving power. Peak I and peak J were both subjected to separation on the VSCTA-
SAX column with a 0.8 M – 1.5 M ammonium bicarbonate gradient. This resulted in 
improvements in peak resolution (Figure 5b and 5c). MS showed that all three structures had the 
same m/z ratio of 549.3 [M-3H]3- (data not shown). It was particularly noteworthy that IMMS on 
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these three isomeric structures revealed that each structure had different ATDs. Peak K displayed 
the most extended conformation with an ATD of 3.74 ms, peak M a slightly more compact 
conformation (3.60 ms), and peak L a much more compact structural conformation (3.46 ms) 
(Figure 5d). MS/MS and compositional analysis was completed on all three of these structures 
(Figure 5e and 5f). Compositional analysis showed that peak K and peak L each contained one 
∆UA - GlcNS6S and two ∆UA2S - GlcNS6S disaccharides whereas peak M contained one 
∆UA2S - GlcNS and two ∆UA2S - GlcNS6S disaccharides. MSMS of these structures showed 
that all three contained a doubly charged product ion of 576 corresponding to an intact dp4 + 
6SO3 (UA2S - GlcNS6S - UA2S - GlcNS6S). Thus the sequence of peaks K and L are defined as 
∆UA - GlcNS6S - UA2S - GlcNS6S - UA2S - GlcNS6S and ∆UA2S - GlcNS6S - UA2S - 
GlcNS6S - UA - GlcNS6S respectively and the sequence of peak M / peak H is ∆UA2S - 
GlcNS6S - UA2S - GlcNS6S - UA2S - GlcNS or ∆UA2S - GlcNS - UA2S - GlcNS6S - UA2S - 
GlcNS6S (Figure S-1). These two structures with identical compositional analysis but, 
disaccharide UA - GlcNS6S at either the reducing end or the non-reducing end, displayed the 
largest ATD difference (3.74 ms and 3.46 ms). This suggests that oligosaccharide conformation 
can have an effect on separations using SAX columns, possibly via the different distribution of 
free electrons affecting the strength of the interaction.  
Conclusions  
Here we demonstrate the isolation, separation and analysis of multiple hexasaccharide structures 
from heparin oligosaccharide starting material. The VSCTA-SAX methodology we describe 
resulted in enhanced resolution compared to previous methods, likely resulting from a 
combination of the weaker displacement salt, the co-ordination of ammonium with the sulfate 
groups and differences in structural conformation and electron distribution. We have 
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demonstrated that VSCTA-SAX provides improved separation of structural isomers compared to 
HILIC and RP-IP, and also removes the need for traditional desalting methods. Volatile salt 
methods for heparin/HS chromatography techniques are increasingly in demand to improve 
yields, which  is crucial since only very small amounts of individual structures are often purified 
from complex starting mixtures. Thus the practicality of subsequent analysis and screening is 
enhanced using VSCTA-SAX. We demonstrate here that the combination of established SEC 
and SAX separation techniques with VSCTA-SAX allowed the separation of 5 isomeric 
structures (dp6 + 8SO3) and their sequence determination in a manner not possible with 
traditional methods alone. We have also applied the method to purification of isomeric heparin 
saccharides for studying selectivity of interactions with the chemokine MCP-1/CCL2 (Miller et 
al, submitted to Analytical Chemistry). We conclude that VSCTA-SAX is a powerful additional 
tool to enhance structure-activity studies on heparin/HS saccharides.  
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Figure 1. CTA-SAX separation of HS standards using non-volatile and volatile buffers. 
Disaccharide standards were injected and eluted from CTA-derived Discovery C18 column using 
a 0-1 M gradient over 60 minutes of: a) ammonium methane sulfonic acid, pH 2.5. b) ammonium 
bicarbonate. Standards: 1 – ΔUA-GlcNAc, 2 – ΔUA-GlcNS, 3 – ΔUA-GlcNAc6S, 4 – ΔUA2S-
GlcNAc, 5 – ΔUA-GlcNS6S, 6 – ΔUA2S-GlcNS, 7 – ΔUA2S-GlcNAc6S, 8 – ΔUA2S-
GlcNS6S.	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Figure 2. SAX separation of a heparin hexasaccharide mixture. The dp6 oligosaccharide 
fraction isolated from SEC (data not shown) was collected and separated using a Propac PA1 
SAX column on a 0-1.4 M NaCl gradient over 90 minutes as described in Methods. Arrowed 
peaks were collected for further separation using subsequent methodologies. 
Figure 3. Purification of minor and major oligosaccharide products using SAX and 
VSCTA-SAX. a) SAX separation of peak A on a Propac PA1 SAX column using a 0.6 – 1.1 M 
NaCl gradient over 60 minutes. b) Peak D was separated further using a VSCTA-SAX column 
on a 0.7 – 1.4 M ammonium bicarbonate gradient B in A over 60 minutes. c) MS of peak E, 
showing a m/z of 509.9 which corresponds to dp6 + 6SO3 + 1Ac. d) MS/MS of peak E at 15 V 
and 20 V. e) Disaccharide analysis of peak E. The lower chromatograms correlates to 
disaccharide standards. The upper trace is disaccharide analysis of peak E. This information 
defined the structure an overall sequence of ∆UA2S - GlcNS6S – UA - GlcNAc6S - UA2S - 
GlcNS. Standards: 3 – ΔUA - GlcNAc6S, 4 – ΔUA2S - GlcNAc, 5 – ΔUA - GlcNS6S, 6 – 
ΔUA2S - GlcNS, 7 – ΔUA2S - GlcNAc6S, 8 – ΔUA2S - GlcNS6S. 
Figure 4. Purification and analysis of isomeric heparin hexasaccharide products from Peak 
B (Figure 2) using SAX and VSCTA-SAX. a) SAX separation of peak B on a Propac PA1 
SAX column using a 0.6 – 1.1 M NaCl gradient over 60 minutes. b) Peak F was separated further 
using a VSCTA-SAX column on a 0.7 – 1.4 M ammonium bicarbonate gradient over 60 minutes. 
c) MS of peak G and H, displayed a m/z of 549.3, which corresponds to dp6 + 8SO3. d) IMMS of 
peak G and peak H. e) MS/MS of peak G and peak H at 15 V. f) The lower chromatogram 
correlates to disaccharide standards, the upper two chromatograms correlates to disaccharide 
analysis of peak G and peak H. This information gave peak G an overall sequence of ∆UA2S - 
GlcNS6S - UA - GlcNS6S - UA2S - GlcNS6S and peak H a sequence of ∆UA2S - GlcNS - 
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UA2S - GlcNS6S - UA2S -GlcNS6S. Standards: 3 – ΔUA - GlcNAc6S, 4 – ΔUA2S - GlcNAc, 5 
– ΔUA - GlcNS6S, 6 – ΔUA2S - GlcNS, 7 – ΔUA2S - GlcNAc6S, 8 – ΔUA2S - GlcNS6S. 
Figure 5. Separation of three isomeric structures. a) Propac PA1 SAX separation of peak C 
on a 0.84 M – 1.2 M NaCl gradient over 60 minutes. b) VSCTA-SAX separation of peak I on a 
0.8 M – 1.5 M ammonium bicarbonate gradient over 60 minutes, isolating peak K. c) VSCTA-
SAX separation of peak J on a 0.8 M – 1.5 M ammonium bicarbonate gradient over 60 min, 
isolating peak L and peak M. d) IMMS separation of peaks K, L and M. e) MS/MS of peaks K, L 
and M at 15 V. f) The lower chromatogram correlates to disaccharide standards, the upper three 
chromatograms correlates to disaccharide analysis of peaks K, L and M. The sequence of peak K 
is ∆UA - GlcNS6S - UA2S - GlcNS6S - UA2S - GlcNS6S, peak L is ∆UA2S - GlcNS6S - UA2S 
- GlcNS6S - UA - GlcNS6S, and peak M is ∆UA2S - GlcNS6S - UA2S - GlcNS6S - UA2S - 
GlcNS. Standards: 3 – ΔUA - GlcNAc6S, 4 – ΔUA2S - GlcNAc, 5 – ΔUA - GlcNS6S, 6 – 
ΔUA2S - GlcNS, 7 – ΔUA2S - GlcNAc6S, 8 – ΔUA2S - GlcNS6S. 
a)	   b)	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Figure 1. CTA-SAX separation of HS standards using non-volatile and volatile buffers.  
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Figure 2. SAX separation of a heparin hexasaccharide mixture.  
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Figure 3. Purification of minor and major oligosaccharide products using SAX and 
VSCTA-SAX.  
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Figure 4. Purification and analysis of isomeric heparin hexasaccharide products from Peak 
B (Figure 2) using SAX and VSCTA-SAX.  
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Figure 5. Separation of three isomeric structures. 
